Al-Dawaa holds 14% local market share, eyes expansion of pharmacy network

14/03/2022 Argaam Special

Mohammed Al-Farraj, CEO of Al-Dawaa Medical Services Co.


Al-Dawaa Medical Services Co. (DMSCO) holds a 14% market share in Saudi Arabia, which offers promising opportunities for more growth.

 

The company has a specific and well-studied plan to expand its network to 1,065 pharmacies by 2025.

 

Al-Dawaa is working on improving the measures related to selecting the locations and designs of new pharmacies, the company told Argaam in an exclusive, adding this measure led to a significant increase in the average sales per square meter, which will, in turn, help the company boost its financial performance through expansion plans.  

 

The company began the construction of a plant in Sudair neighborhood, expecting to commence production in early 2023. Meanwhile, the medical equipment and devices represent a new market for the company.

 

Accordingly, the company will be well-qualified to benefit from the strong growth drivers in the Saudi healthcare sector.

 

It also elaborated that Al-Dawaa e-commerce platform recorded the fastest growth in the Kingdom’s retail pharmaceutical industry. In 2021, the platform accounted for 5% of the company’s net sales, compared to 1.5% in 2019.

 

The company added that it is able to deliver a robust value to shareholders in the long term, either through increasing the capital value of its assets or through its dividend policy. Going forward, Al-Dawaa aims to pay out dividends ranging between 50% and 60% of total profit.

 

Here's the full interview about the company’s business and plans:

 

Q: How do you see the pharmaceutical sector in Saudi Arabia, in terms of market size, spending, purchasing power and profit margins?

 

A: The retail pharmaceutical market in the Kingdom continues to show strong growth potential. Al-Dawaa is well-established to benefit from this valuable opportunity. Today, we see growing demand for prescribed medications and over-the-counter (OTC) medicines, in addition to cosmetics and body care products, as youth make up a large part of the Saudi population. Spending on medications is expected to hit SAR 43.8 billion by 2025, in parallel with a rise in spending on healthcare services. Pharmacy chains, such as Al-Dawaa chains, are among the biggest beneficiaries of this growth in spending. The pharmacy chains are forecast to see a compound annual growth rate (CAGR) of 5.9% in prescribed medications by 2025.

 

We also continue to develop new products and partnerships to enhance our ability to leverage this growth. For example, Dawaok program has improved the adherence of people with chronic diseases to prescribed medications as well as the correct advice and accurate dosages by 118% since its launch in 2015. This was, accordingly, reflected on increasing our customers’ loyalty and sales.

 

Finally, we are currently developing our own nutritional supplement brands, such as Ronzac and Hollins, to capitalize on consumer demand for healthcare products. Thus, launching our own brands allows us to further enhance our business’ profitability and take advantage of new marketing channels outside our existing pharmacies network.

 

Q: How many pharmacies and transportation fleet does the company operate? How are they distributed? How much is your market share?

 

A: Al-Dawaa currently has more than 900 pharmacies in 130 cities, towns and villages across Saudi Arabia. Our market share stands at 14%, which provides us with promising opportunities for further growth, supported by our unique logistics infrastructure that is based on the latest technology.

 

Our fully automated main warehouse in Sudayr area currently receives and delivers 60 million units per month. It has the ability to expand the handling volume for a larger number of units.

 

In addition, our fleet includes more than 600 vehicles equipped with advanced tracking technology that ensures smooth and safe transportation and delivery of our pharmaceuticals.

 

Q: What is the goal behind expansion in the pharmacy network this year?

 

A: The expansion of our pharmacy network is one of the key pillars for Al-Dawaa growth. The company has a specific and well-studied plan to expand its network to 1,065 pharmacies by 2025. Al-Dawaa is also working on selecting the locations and designs of new pharmacies, based on thorough studies and strict standards. In the last few years, we improved the measures related to selecting the locations and designs of new pharmacies. This move led to a significant increase in the average sales per square meter, thanks to the new branches we opened during that period. This expansion will in turn help the company boost its financial performance while pursuing its expansion plans.

 

Q: What about the contribution of Al-Dawaa e-channels to total sales?

 

A: Al-Dawaa e-commerce platform recorded the fastest growth in the Kingdom’s retail pharmaceutical industry. In 2021, the platform accounted for 5% of the company’s net sales, compared to 1.5% in 2019. We are excited about the available opportunities in this respect. We also have a solid track record for innovation and digital excellence. This applies to our e-commerce offers, as the company has its own mobile application, unlike peers in the sector. Al-Dawaa application has been downloaded by over 800,000 clients so far.

 

Q: Can you give us more details about the company’s plans to enter the medical equipment market? And what about the expected investments in this market?


A: Al-Dawaa has strong ties with government authorities in the Kingdom. Through our cooperation with the Ministry of Health, we found that there is a dire need for the localization of the medical equipment and devices industry. To this end, we broke ground on a new plant in Sudair neighborhood and we expect to commence production in early 2023. Meanwhile, the medical equipment and devices represent a new market for the company.

 

Accordingly, the company will be well-qualified to benefit from the strong growth drivers in the Saudi healthcare sector. Al-Dawaa aims to have a leading position in the localization of the medical equipment and devices industry.

 

Q: Any message to your partners?

 

A: We are pleased to welcome new investors in the company, after the completion of the initial public offering (IPO). Al-Dawaa is in a perfect position to seize available growth opportunities in the market. We are confident that we can deliver a robust value to shareholders in the long term, either through increasing the capital value of our assets or through our dividend policy. Going forward, Al-Dawaa aims to pay out dividends ranging between 50% and 60% of total profit. 

Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Most Read